Member Info for Bermudashorts

Chelsea,

'It is paramount that a cancer patient and/or loved ones can talk abut their feelings' ...........................................

Of course it is and I don't think anyone has ever suggested otherwise.

miavoce,

It's also possible that she simply hasn't had the results yet.

Wild,

I hope that's not the case.

https://www.globenewswire.com/news-release/2022/11/30/2565060/0/en/Directorate-change.html

C7

I'm really sorry that having read my response to hasiba's 10.28, you chose to call me out for abuse. We have previously discussed hasiba's comments re. Scancell, so you were aware of them, but under the circumstances may well have forgotten.

I'll not comment any further other than to say that whilst I'm sorry to read your accusation of abuse, I'm even more sorry to read how poorly you have been and very much hope things improve for you.

hasiba,

I thought you had filtered me? Make your mind up. I have no issues whatsoever with your trading posts. However, your posts that Scancell didn't really have any labs and that they didn't have the technical expertise to run a phase I trial were simply not true.

As for my own posting history - it's there for all to see, I have nothing to hide and I have certainly never attempted to trash a company to suit my trading position. Redx is/has been a great investment for me and it seems that Redmile agree. MTFB was a loss and I had sold DDDD prior to suspension. Both MTFB and DDDD are excellent examples of risk in biotech. One had successfull phase 3 trials in the bag and still fell at the last hurdle and the other had really promising science (esp. in oncology) and big licensing deals with Merck, yet debt funding combined with a poorly timed and poorly executed NASDAQ listing show that sometimes it's not all about the science.

ee

Scancell have already informed the market that the first patient on the full Modi1 dose has demonstrated a partial response. I'm not sure there is any requirement for an RNS if subsequent scans show that response is maintained or even further tumour shrinkage. I'm certainly not expecting another Modi1 RNS until the planned announcement of immunogenicity and safety results due by y/e.

hasiba

.........and of course it's much easier to filter posters who are able and willing to call you out on your bullsh*t than to respond to them. I think most on here understand where you're coming from.

The other day I mentioned that the status of Covidity trial on clinicaltrials.gov had been updated to 'active not recruiting' meaning that recruitment was complete, but the trial was ongoing with patients potentially still being dosed/followed up. This tallied with the trial record on SANCTR, the South African Clinical Trials Registry which was updated a month ago to show 'Closed to recruitment,follow-up continuing'.

Good to see that there has now been a further update on SANCTR with the recruitment status being changed to 'completed - All study participants have completed the study visits as per the protocol.'

Guess they're now busy verifying and analysing the data and hopefully on track for publication of top line results. Worth remembering that these results are as much about proof of concept for Scancell's Avidimab platform as they are about Covid.

Yes, excellent news

Moving on, apologies if this has already been posted, but it won't harm to have another look.

'This comparative undervaluation is ripe for change. Big investors in the US and Asia are eyeing up the UK, recognising there are bargains to be had. That interest could turn into share purchases or outright acquisitions.

The UK life sciences sector has been overlooked and underfunded for years but it is packed full of fascinating companies working their utmost to find cures and treatments for some of the most pernicious diseases in the world. '

https://www.thisismoney.co.uk/money/investing/article-11471939/MIDAS-SHARE-TIPS-life-sciences-start-wealth-booster.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.261764557.1739495891.1669545659-1809660832.1607947364

Chester,

This will also be my last post on the subject. Konar is probably one of the best researched and most balanced posters on this bb and has been for years. He has a different opinion to you and has given good reasons why he's formed that opinion. That doesn't mean he's got a warped mind or that he's following an agenda as you suggested.

Have you thought that it may have been a Scancell holder posting with the best of intentions, who perhaps didn't understand the implications of what they were doing? So rather than being a cynical act, it was just a case of over enthusiasm and naivety. If that is the case then it's good that it has been raised and discussed on the bb and we should be thanking Konar.

Scrabbling for the moral high ground or raising some valid points regarding a highly emotive issue?

It seems many believe that the person prompting patient 1 is highly likely to be a Scancell shareholder. I think it's also obvious that absolutely nobody would do such a thing out of malice, so I'm sorry the idea that it's an ex-poster/ Scancell hater is a non-starter IMO. If it is a Scancell holder, I wonder whether the've stopped to think how embarrassing this could be for Scancell?

AB124 raises a really important point that we're conveniently overlooking. I remember when a poster visited this bb and tried to claim that there was an issue with one of Scancell's patents. It was nonsense of course, but people didn't have the information or experience to know that and so they sold. From memory, the share price dropped by over 5% within an hour.

Communication of clinical trial results is a complex and sensitive issue. Information can be easily misunderstood or misinterpreted. It's all well and good to discuss the macmillan site when the information is so positive, but supposing something negative appears? What then? It may well be totally unrelated to Moditope but the only people who will know are those with access to the raw data and the knowledge and skills to analyse it - ie. Scancell. By constantly linking to and discussing the macmillan site, we are in effect jeopardising Scancell's ability to control the dissemination of results and that is a very bad thing.

IMO

Dalester,

' We know more about what the expectation was from a clinical standpoint than probably Trish did'

Whilst I understand and appreciate the points you're trying to make, I very much doubt that the above is true.

Drew,

Yes, clinical trial patients are told the name of the drug. If it's a randomised and blinded study then they won't know whether they're on the placebo or treatment arm, but they'll certainly know the name of the drug being trialled. Burble will correct me if I'm wrong but I'm pretty sure giving patients details of the drug is part and parcel of obtaining informed consent.

Konar,

Absolutely - post rec

Covidity trial record has now been updated to show 'active not recruiting' reflecting the fact that recruitment is complete.

https://clinicaltrials.gov/ct2/show/NCT05047445?term=scancell&draw=2&rank=2

Link below is to Conviction Life Sciences IPO presentation. Slides 19 onwards might be of interest to SCLP holders. With reference to slide no. 26, I'm pretty sure Company A is another Redmile investee company, Redx pharma and Company B is Angle. Also note Genmab get a mention.

https://clsc-docs.s3-eu-west-2.amazonaws.com/CLSC-Investor-Presentation-NOV-2022.pdf

Dalester,

I hope not.

In order to obtain ethics committee approval before the trial starts, all study investigators must disclose any financial interests in the sponsoring company and they must continue to update this disclosure throughout the duration of the study. It would be unethical for study investigators to buy or sell shares in Scancell as they are restricted by the usual insider trading regulations. Moreover, it could jeopardise the integrity of the trial because it introduces the potential for bias.

rigga - Further Modi1 update is due within the next few weeks - 'The Company expects further safety and immunogenicity data to be available in H2 2022'

Johnny - well spotted, thanks

Chelsea,

Yes, there were some really useful comments regarding funding. There seems to be some sort of paranoia when it comes to discussing funding and it's treated as a taboo subject by some. Of course the reality is that the funding position is a vital part of the investment decision making process and good communication from the board on finances is important.

Lindy Durrant laid out the cash position and explained which projects are fully funded and which will require further funding. She also made it clear that that the form of that funding will obviously depend on whether or not they are able to sign further deals, but that they may carry out another funding round at some point. It was good to see Lindy discuss funding and future needs in an open, realistic and relaxed fashion -as you'd expect of any decent CEO.

I would much prefer another round of funding rather than see them hold up the clinical development of Modi2/mAbs or cut a deal before data from existing trials is mature enough to increase valuations. As Chester has said, hopefully any future funding rounds will be from a much higher base and Martin Diggle's comments leave no doubt as to the level of support from existing iis. It would also be a good opportunity to bring in more specialist life science investors.

So all in all the comments at the AGM around funding were reassuring. As Scancell has shown over the last couple of years, even a bio with the best science needs funding and it's not something to be feared - it's the ones who don't/can't raise that you should worry about.

lofas,

I think it's important to remember that whether a trial is a success or failure depends on whether it meets its endpoints. This is a phase I study and as such isn't powered for proof of efficacy. The primary endpoints are all around safety and secondary are about immunogenicity - the type of immune response generated. I suspect/hope that based on these outcome measures the trial will be a success. There are also some exploratory endpoints and it will be interesting to see responses broken down by number of doses and time since last dose.

Given the current environment and the demands of Scancell's oncology pipeline it will be interesting to see the next steps for Covidity. Regardless of that outcome however, Scancell have in effect just completed a clinical trial for Avidimab and I'm sure the data will be invaluable.